Immunome, Inc. - IMNM STOCK NEWS

Immunome, Inc. (NASDAQ: IMNM) announced a peer-reviewed study in Clinical & Translational Immunology, focusing on B cell repertoires in breast cancer patients. The study, conducted with the University of Vermont and the University of Pennsylvania, explores tumor-specific B cell clonal lineages. Key findings include increased frequencies of tumor-specific B cells in tumors versus blood, and insights into the relationship between tumor features and B cell targeting. Immunome aims to leverage these findings for innovative cancer therapies.

Immunome, a biopharmaceutical firm, reported its Q2 2022 results, marking its transition into a clinical stage company. The company continues to dose patients in its Phase 1b study of the COVID-19 antibody cocktail, IMM-BCP-01, which retains neutralizing activity against prevalent Omicron subvariants. Immunome also provided updates on its oncology candidate, IMM-ONC-01, emphasizing its potential in multiple cancers. Financially, R&D expenses were $5.7 million, with a net loss of $8.9 million. Cash reserves stood at $34.6 million as of June 30, 2022.

Immunome Inc. (NASDAQ: IMNM) announces that its COVID-19 therapeutic, IMM-BCP-01, showed effectiveness against the BA.4/5 and BA.2.12.1 subvariants in recent pseudovirus tests. This three-antibody cocktail is currently in Phase 1b clinical trials, with topline data expected in the second half of 2022. Funded by the U.S. Department of Defense, the investigational treatment aims to address the ongoing pandemic. As of June 25, 2022, these subvariants constituted over 90% of COVID-19 cases in the U.S.

Immunome (NASDAQ: IMNM) has initiated a Phase 1b clinical trial of its antibody cocktail, IMM-BCP-01, for treating COVID-19, with the first patient dosed. The study focuses on safety as the primary endpoint, assessing pharmacokinetics and virology as secondary outcomes. Topline results are expected later this year. Previous data indicates that IMM-BCP-01 effectively targets Omicron variants in vitro. The trial is funded by the U.S. Department of Defense, underscoring its significance in combating COVID-19.

Immunome, Inc. (NASDAQ: IMNM) has announced that its President and CEO, Purnanand Sarma, PhD, will present at the Jefferies Healthcare Conference on June 9 at 2:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with a replay available for 90 days post-event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell platform, targeting oncology and infectious diseases, including COVID-19. For more details, visit www.immunome.com.

Immunome, Inc. (Nasdaq: IMNM) announced significant advancements in its lead oncology program, IMM-ONC-01, a novel therapy targeting the immunosuppressive cytokine IL-38. Preclinical research shows high mRNA expression of IL-38 in over 60 cancer sub-types, particularly in high unmet need cancers like Gastroesophageal and Head and Neck Squamous Carcinomas. Immunome collaborates with Fox Chase Cancer Center to confirm IL-38 protein expression in patients. The company plans to file an IND in 2H 2022 to expedite clinical development.

Immunome, Inc. (Nasdaq: IMNM) announced promising results from its COVID-19 antibody cocktail, IMM-BCP-01, which effectively neutralized the Omicron variant in in vivo studies with hamsters. The antibody IMM20253 also showed effectiveness against the BA.2 subvariant in in vitro tests. The research indicates that the cocktail retains substantial activity against various Omicron subvariants, enhancing confidence in their Phase 1b study. The study is supported by the U.S. Department of Defense.

Immunome, Inc. (Nasdaq: IMNM) reported its Q1 2022 financial results, highlighting FDA clearance for its Phase 1b clinical trial of the COVID-19 antibody cocktail, IMM-BCP-01. This therapy aims to address the urgent need for effective COVID-19 treatments amid new variants. The company also progresses its IL-38 targeting antibody treatment, IMM-ONC-01, with an IND submission planned for late 2022. Financially, R&D expenses were $8.1 million, G&A expenses were $3.6 million, and a net loss of $11.7 million was recorded. Cash reserves stood at $42.9 million as of March 31, 2022.

Immunome, Inc. (Nasdaq: IMNM) has received a safe-to-proceed notification from the U.S. FDA for its IMM-BCP-01 investigational new drug application, allowing progress towards a Phase 1b clinical trial. The company’s antibody cocktail has shown promising in vitro efficacy against the Omicron variant of COVID-19, neutralizing it with significantly higher potency than existing treatments. Financially, Immunome reported a net loss of $7.9M for Q4 2021, with cash reserves of $49.2M as of December 31, 2021. Ongoing projects include the development of IMM-ONC-01 for targeting IL-38 in oncology.